Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
The youngest population under 50 years old (P50) with lung cancer (LC) in the French nationwide real-life KBP cohorts: Evolution since 2000. Clinical outcomes of maintenance durvalumab after ...
This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results